HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.
Stocks · News reference
Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027
8-K filing — Upstream Bio, Inc. (UPB)
Filed: 2026-09-01 AccNo: 0001193125-26-377485 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.